STOCK TITAN

BridgeBio Oncology: Deerfield reports 3.91% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. (BBOT) is the issuer named in an amended Schedule 13G reporting beneficial ownership of its common stock. For the September 30, 2026 event date, Deerfield Management Company, L.P. and James E. Flynn each reported 3,138,167 shares, or 3.91%, with shared voting and dispositive power and no sole voting or dispositive power. The two underlying funds, Deerfield Partners, L.P. and Deerfield Private Design Fund V, L.P., reported 1,569,083 and 1,569,084 shares, respectively, each representing 1.96%. The figures overlap because the larger reported interests comprise shares held by those funds.

Reported beneficial ownership 3,138,167 shares Reported by Deerfield Management Company, L.P. and James E. Flynn; September 30, 2026 event date
Percent of class 3.91% Reported by Deerfield Management Company, L.P. and James E. Flynn
Deerfield Partners, L.P. shares 1,569,083 shares Reported beneficial ownership; 1.96% of the class
Deerfield Private Design Fund V, L.P. shares 1,569,084 shares Reported beneficial ownership; 1.96% of the class
Aggregate Amount Beneficially Owned regulatory
"Aggregate Amount Beneficially Owned by Each Reporting Person"
Shared Voting Power regulatory
"Shared Voting Power 1,569,083"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Shared Dispositive Power regulatory
"Shared Dispositive Power 1,569,083"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BBOT shares did Deerfield report owning?

Deerfield Management Company, L.P. and James E. Flynn each reported beneficial ownership of 3,138,167 BBOT shares, or 3.91%, for the September 30, 2026 event date. The reported interests comprise shares held by Deerfield Partners, L.P. and Deerfield Private Design Fund V, L.P.

Who had voting and dispositive power over the reported BBOT shares?

The reporting persons disclosed shared voting and dispositive power over their reported shares and zero sole voting or dispositive power. Deerfield Management Company, L.P. and James E. Flynn each reported shared power over 3,138,167 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





107924102

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: Comment for Type of Reporting Person: Comprised of shares of Common Stock held by Deerfield Partners, L.P., of which Deerfield Mgmt, L.P. is the general partner.


SCHEDULE 13G




Comment for Type of Reporting Person: Comment for Type of Reporting Person: Comprised of shares of common stock held by Deerfield Private Design Fund V, L.P., of which Deerfield Mgmt V, L.P. is the general partner.


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G




Comment for Type of Reporting Person: Comment for Type of Reporting Person: Comprised of shares of Common Stock held by Deerfield Partners, L.P. and Deerfield Private Design Fund V, L.P., of which Deerfield Management Company, L.P. is the investment advisor.


SCHEDULE 13G




Comment for Type of Reporting Person: Comment for Type of Reporting Person: Comprised of shares of Common Stock held by Deerfield Partners, L.P. and Deerfield Private Design Fund V, L.P.


SCHEDULE 13G



Deerfield Mgmt, L.P.
Signature:/s/ Jonathan Isler
Name/Title:Jonathan Isler, Attorney-In-Fact
Date:11/13/2026
Deerfield Mgmt V, L.P.
Signature:/s/ Jonathan Isler
Name/Title:Jonathan Isler, Attorney-In-Fact
Date:11/13/2026
Deerfield Partners, L.P.
Signature:/s/ Jonathan Isler
Name/Title:Jonathan Isler, Attorney-In-Fact
Date:11/13/2026
Deerfield Private Design Fund V, L.P.
Signature:/s/ Jonathan Isler
Name/Title:Jonathan Isler, Attorney-In-Fact
Date:11/13/2026
Deerfield Management Company, L.P.
Signature:/s/ Jonathan Isler
Name/Title:Jonathan Isler, Attorney-In-Fact
Date:11/13/2026
James E. Flynn
Signature:/s/ Jonathan Isler
Name/Title:Jonathan Isler, Attorney-In-Fact
Date:11/13/2026
Exhibit Information

Exhibit A. Joint Filing Agreement. Exhibit B. Item 8 Statement. Exhibit C. Power of Attorney (1). (1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.

Keep reading